Topical preventative medicament against burns-related systemic inflammatory response syndrome

Abstract

A topical preventative medicament against burns-related systemic inflammatory response syndrome containing a low-molecular-weight chaperone as the main active ingredient.

What is claimed is: 
     
         1 . A topical preventative medicament against burns-related systemic inflammatory response syndrome containing a low-molecular-weight chaperone as the main active ingredient. 
     
     
         2 . The topical preventative medicament against burns-related systemic inflammatory response syndrome according to  claim 1 , characterized in that it further contains a water-soluble fullerene. 
     
     
         3 . The topical preventative medicament against burns-related systemic inflammatory response syndrome according to  claim 1 , characterized in that it further contains histamine. 
     
     
         4 . The topical preventative medicament against burns-related systemic inflammatory response syndrome according to  claim 1 , characterized in that the low-molecular-weight chaperone is αB-crystallin. 
     
     
         5 . A medicament comprising a topical preparation containing an effective amount of a low molecular-weight chaperone. 
     
     
         6 . The medicament of  claim 5 , wherein the chaperone is a sHSP. 
     
     
         7 . The medicament of  claim 6 , wherein the chaperone is αB-crystallin. 
     
     
         8 . The medicament of  claim 5 , wherein the medicament is an aqueous solution. 
     
     
         9 . The medicament of  claim 8 , wherein the aqueous solution is a buffered solution. 
     
     
         10 . The medicament of  claim 8 , further comprising one or more of histamine and a soluble fullerene. 
     
     
         11 . The medicament of  claim 8 , wherein the chaperone is present at a concentration of 1-100 μM, 10-80 μM or 25-75 μM. 
     
     
         12 . The medicament of  claim 11 , further comprising histamine present at a concentration of 0.05-1.0 μM, 0.05-0.5 μM or 0.05-0.1 μM. 
     
     
         13 . A spray bottle containing a topical preparation containing an effective amount of a low molecular-weight chaperone. 
     
     
         14 . The spray bottle of  claim 13 , wherein the chaperone is a sHSP. 
     
     
         15 . The spray bottle of  claim 13  wherein the chaperone is αB-crystallin. 
     
     
         16 . The spray bottle of  claim 13 , wherein the medicament is an aqueous solution. 
     
     
         17 . The spray bottle of  claim 16 , wherein the aqueous solution is a buffered solution. 
     
     
         18 . The spray bottle of  claim 16 , further comprising one or more of histamine and a soluble fullerene. 
     
     
         19 . The spray bottle of  claim 16 , wherein the chaperone is present at a concentration of 1-100 μM, 10-80 μM or 25-75 μM. 
     
     
         20 . The spray bottle of  claim 16 , further comprising histamine present at a concentration of 0.05-1.0 μM, 0.05-0.5 μM or 0.05-0.1 μM. 
     
     
         21 .- 28 . (canceled)